vs
Amphastar Pharmaceuticals, Inc.（AMPH）与合众银行（TBBK）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是合众银行的1.1倍（$183.1M vs $161.3M），合众银行净利率更高（37.2% vs 13.3%，领先23.9%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -8.0%），过去两年合众银行的营收复合增速更高（13.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
合众银行（U.S. Bancorp）是总部位于美国明尼苏达州明尼阿波利斯的跨国银行机构，注册地为特拉华州，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会列为系统重要性金融机构，旗下核心运营主体为美国银行全国协会，提供银行、投资、按揭等多元金融服务。
AMPH vs TBBK — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$161.3M
营收增速更快
AMPH
高出6.2%
-8.0%
净利率更高
TBBK
高出23.9%
13.3%
两年增速更快
TBBK
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $161.3M |
| 净利润 | $24.4M | $60.1M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | — |
| 净利率 | 13.3% | 37.2% |
| 营收同比 | -1.8% | -8.0% |
| 净利润同比 | -35.7% | -1.5% |
| 每股收益（稀释后） | $0.51 | $1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHTBBK
| Q1 26 | — | $161.3M | ||
| Q4 25 | $183.1M | $172.6M | ||
| Q3 25 | $191.8M | $174.6M | ||
| Q2 25 | $174.4M | $181.2M | ||
| Q1 25 | $170.5M | $175.4M | ||
| Q4 24 | $186.5M | $159.6M | ||
| Q3 24 | $191.2M | $125.8M | ||
| Q2 24 | $182.4M | $124.5M |
净利润AMPHTBBK
| Q1 26 | — | $60.1M | ||
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $54.9M | ||
| Q2 25 | $31.0M | $59.8M | ||
| Q1 25 | $25.3M | $57.2M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $51.5M | ||
| Q2 24 | $37.9M | $53.7M |
毛利率AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
营业利润率AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 43.4% | ||
| Q3 25 | 13.2% | 41.9% | ||
| Q2 25 | 24.2% | 43.9% | ||
| Q1 25 | 21.9% | 42.9% | ||
| Q4 24 | 24.2% | 47.9% | ||
| Q3 24 | 29.8% | 54.9% | ||
| Q2 24 | 30.3% | 57.7% |
净利率AMPHTBBK
| Q1 26 | — | 37.2% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 31.5% | ||
| Q2 25 | 17.8% | 33.0% | ||
| Q1 25 | 14.8% | 32.6% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 40.9% | ||
| Q2 24 | 20.8% | 43.1% |
每股收益（稀释后）AMPHTBBK
| Q1 26 | — | $1.41 | ||
| Q4 25 | $0.51 | $1.28 | ||
| Q3 25 | $0.37 | $1.18 | ||
| Q2 25 | $0.64 | $1.27 | ||
| Q1 25 | $0.51 | $1.19 | ||
| Q4 24 | $0.74 | $1.14 | ||
| Q3 24 | $0.78 | $1.04 | ||
| Q2 24 | $0.73 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | — |
| 总债务越低越好 | $608.7M | $483.7M |
| 股东权益账面价值 | $788.8M | $697.0M |
| 总资产 | $1.6B | $9.9B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | $112.6M | ||
| Q3 25 | $276.2M | $84.7M | ||
| Q2 25 | $231.8M | $340.3M | ||
| Q1 25 | $236.9M | $1.0B | ||
| Q4 24 | $221.6M | $570.1M | ||
| Q3 24 | $250.5M | $55.8M | ||
| Q2 24 | $217.8M | $405.6M |
总债务AMPHTBBK
| Q1 26 | — | $483.7M | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $14.1M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHTBBK
| Q1 26 | — | $697.0M | ||
| Q4 25 | $788.8M | $689.8M | ||
| Q3 25 | $776.7M | $778.2M | ||
| Q2 25 | $757.5M | $860.3M | ||
| Q1 25 | $751.3M | $829.7M | ||
| Q4 24 | $732.3M | $789.8M | ||
| Q3 24 | $727.7M | $815.3M | ||
| Q2 24 | $713.3M | $777.0M |
总资产AMPHTBBK
| Q1 26 | — | $9.9B | ||
| Q4 25 | $1.6B | $9.4B | ||
| Q3 25 | $1.7B | $8.6B | ||
| Q2 25 | $1.6B | $8.8B | ||
| Q1 25 | $1.6B | $9.4B | ||
| Q4 24 | $1.6B | $8.7B | ||
| Q3 24 | $1.5B | $8.1B | ||
| Q2 24 | $1.5B | $8.1B |
负债/权益比AMPHTBBK
| Q1 26 | — | 0.69× | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.02× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $265.0M | ||
| Q3 25 | $52.6M | $78.2M | ||
| Q2 25 | $35.6M | $85.9M | ||
| Q1 25 | $35.1M | $132.5M | ||
| Q4 24 | $29.0M | $209.9M | ||
| Q3 24 | $60.0M | $50.8M | ||
| Q2 24 | $69.1M | $17.1M |
自由现金流AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $257.9M | ||
| Q3 25 | $47.2M | $77.6M | ||
| Q2 25 | $25.0M | $85.4M | ||
| Q1 25 | $24.4M | $131.7M | ||
| Q4 24 | $16.6M | $204.9M | ||
| Q3 24 | $46.2M | $49.7M | ||
| Q2 24 | $63.1M | $15.5M |
自由现金流率AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 149.4% | ||
| Q3 25 | 24.6% | 44.4% | ||
| Q2 25 | 14.3% | 47.1% | ||
| Q1 25 | 14.3% | 75.1% | ||
| Q4 24 | 8.9% | 128.4% | ||
| Q3 24 | 24.1% | 39.5% | ||
| Q2 24 | 34.6% | 12.4% |
资本支出强度AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 4.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.3% | ||
| Q1 25 | 6.3% | 0.4% | ||
| Q4 24 | 6.7% | 3.1% | ||
| Q3 24 | 7.2% | 0.9% | ||
| Q2 24 | 3.3% | 1.3% |
现金转化率AMPHTBBK
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.42× | ||
| Q2 25 | 1.15× | 1.44× | ||
| Q1 25 | 1.39× | 2.32× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 0.99× | ||
| Q2 24 | 1.82× | 0.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TBBK
暂无分部数据
